Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mass Clear all

Conditions: Osteopenia, Prematurity
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more

Conditions: Hip Fracture
Interventions: Exercise Plus Program; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 65 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 3
States / cities: Baltimore, Maryland • Randallstown, Maryland • Towson, Maryland

Conditions: Osteoporosis
Interventions: LY2541546, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Gainesville, Georgia • Bethesda, Maryland

Conditions: Indicated for EOSedge Imaging
Interventions: EOSedge imaging; Radiation
Lead sponsor: Alphatec Spine, Inc.; Industry
Eligibility: 20 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fishers, Indiana

Conditions: Osteoporosis
Interventions: Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 15
States / cities: Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more

Conditions: Body Composition, Muscle Function, GLP-1, Estrogen Level
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Bone Mineral Density, Body Fat Distribution, Insulin Homeostasis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 10 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis
Interventions: Bodyweight training; Behavioral
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 40 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Osilodrostat (Isturisa); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Effect of Treatment on Bone Mineral Density
Interventions: enclomiphene citrate, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 17
States / cities: Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more

Conditions: Spinal Cord Injury
Interventions: Acute Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
Interventions: Transdermal estradiol; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bone Densitometry
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Bone Health
Interventions: Calcium rich diet; Other
Lead sponsor: Creighton University; Other
Eligibility: 9 Years to 9 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Osteoporosis
Interventions: Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more

Conditions: Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Zoledronic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Obesity, Osteoarthritis
Interventions: Vest, Diet; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years to 79 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lupus Erythematosus, Systemic
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 7 Years to 22 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-associated Co-morbidities
Interventions: conventional vitamin D treatment, tiered/titrated vitamin D dosing; Dietary Supplement · Drug
Lead sponsor: Andrea Branch; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoporosis
Interventions: Apomine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 2
States / cities: Omaha, Nebraska • West Haverstraw, New York

Conditions: Marfan Syndrome
Interventions: Exercise Intervention Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteopenic Women
Interventions: 2 POMx Capsules, 2 placebo Capsules; Dietary Supplement
Lead sponsor: POM Wonderful LLC; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Proton Pump Inhibitor Therapy and Bone Density in Premature Infants

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

BHS4 - Bone/Muscle Changes Following Hip Fracture in Older White Women

A Study of LY2541546 in Women With Low Bone Mineral Density

Bone Mineral Density Precision Study

The Forteo Alendronate Comparator Trial

GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

The Bone-Fat-Pancreas Axis in Children

Effects of a Weight Based Training Program on MS Patients

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury

The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

T-score Comparability Between GE Lunar Prodigy and Norland Excel Densitometers

Study of the Effect of a Calcium-rich Diet on Bone Health in Girls

Transition From Alendronate to Romosozumab (AMG 785)

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

Arthritis Pilot for Preserving Muscle While Losing Weight

Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

Vitamin D Supplements for HIV-positive Patients on cART

An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass

Marfan Syndrome Moderate Exercise Pilot

Pomegranate Extract Biomarker Study in Osteopenic Women